While the statistics remain stark—lung cancer is the most common type of cancer worldwide and has the highest death ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

The University of Kentucky Markey Cancer Center has treated the first patient in the U.S. with a new immunotherapy for small ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Saudi Arabia approves Anktiva, an IL-15 immunotherapy, for bladder and lung cancer, marking its first regulatory clearance ...

A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.

In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and ...

Following initiation of elexacaftor/tezacaftor/ivacaftor, Lung Clearance Index decreases in children with cystic fibrosis, ...